Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | MTNR1B | P49286 | 8/20 | 0.50 |
| ▸ | MTNR1A | P48039 | 7/20 | 0.49 |
| ▸ | CES2 | O00748 | 1/20 | 0.49 |
| ▸ | CES1 | P23141 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10344222 | 0.93 | KMT2A (0.51) | ALDH1A1TSHRMAPK1TDP1L3MBTL1 | |
| SCHEMBL30463307 | 0.85 | CES2 (0.59) | LMNAMTNR1BMTNR1ACES2CES1 | |
| SCHEMBL8048513 | 0.85 | CES2 (0.59) | LMNAMTNR1BMTNR1ACES2CES1 | |
| SCHEMBL13960012 | 0.85 | KDM4E (0.47) | ALDH1A1TSHRMAPK1TDP1L3MBTL1 | |
| SCHEMBL308933 | 0.84 | LMNA (0.62) | MAPK1TDP1L3MBTL1LMNAKMT2A | |
| SCHEMBL9410965 | 0.83 | CYP3A4 (0.61) | L3MBTL1LMNAKMT2AESR1ESR2 | |
| SCHEMBL28561189 | 0.82 | MTNR1B (0.49) | LMNAMTNR1BMTNR1ACES2CES1 | |
| SCHEMBL28859166 | 0.82 | ALDH1A1 (0.51) | ALDH1A1TSHRMAPK1TDP1L3MBTL1 | |
| SCHEMBL6894576 | 0.82 | GAA (0.51) | ALDH1A1TSHRLMNACES2CES1 | |
| SCHEMBL13135118 | 0.82 | MTNR1B (0.57) | LMNAMTNR1BMTNR1ACES2CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6677331-B2 | HAVING SUBSTITUTED IMIDAZO(5,1-B)THIAZOLE GROUP AT 2-POSITION; MICROBIOCIDES AGAINST BETA-LACTAMASE PRODUCING BACTERIA AND RESISTANT PSEUDOMONAS | MEIJI SEIKA KAISHA, LTD. (JP) | 2004-01-13 | — | — | US | disclosed |
| US-20030149016-A1 | Novel carbapenem derivatives | KANO YUKO (JP) | 2003-08-07 | — | — | US | disclosed |
| EP-1101766-A1 | NOVEL CARBAPENEM DERIVATIVES | MEIJI SEIKA KAISHA LTD. (JP) | 2001-05-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030149016-A1 | Novel carbapenem derivatives | DPEP1, TMPRSS15, STK35 | ALDH1A1 1161/4885TSHR 4209/4885MAPK1 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.